<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Publications

  • Reset
TITLE DATE AUTHOR MODEL(S) DISEASE SUB TYPE DISEASE TYPE THERAPEUTIC AREA MODEL TYPE
Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models 2017 B Baoan Hong et. al. KI2367, KI2368 RCC - Kidney Cancer Kidney Cancer Oncology PDX
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. 2022 B Bram Herpers et. al. NA NA NA Oncology Organoids
Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models 2023 Binchen Mao et. al. NA NA NA NA CDX, PDX, Sygeneic
Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma 2023 Binghua Li LI0050, LI0334, LI0348, LI0574, LI0612, LI0752, LI0801, LI1005, LI1025, LI1035, LI1054, LI1057, LI1068, LI1069, LI1074, LI1078, LI1081, LI1088, LI1097, LI1098, LI1646, LI6206, LI6664 NA Liver Cancer Liver Cancer Treatment PDX
In Vivo Pharmacology Models for Cancer Target Research 2019 D Dawei Chen et. al. AD0484, AL5514, AL5518, AL5521, AL8223 ADC - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder Cancer, TCC - Bladder Cancer Adrenal gland Cancer Oncology CDX, GEMM, HuCell
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity 2018 DAR Daniel A R Heisey et. al. SA10233 Ewing's Sarcoma - Sarcoma Sarcoma NA PDX
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model 2024 Gaëlle H. Martin NA NA NA Immuno-Oncology NA
A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification 2018 H Hanting Zhu et. al. ES0026, ES0042, ES0110, ES0136, ES0141, ES0172, ES0176, ES0178, ES0191, ES0195, ES0199, ES0201, ES0204, ES0215, ES0219, ES2116 ESCC - Esophageal Cancer Esophageal Cancer Oncology PDX
HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models 2023 Hang Ke et. al. huCD47-A20 B-lymphoma, Karpas-299 T-lymphoma, LY12962, LY12966, LY2264, LY2266, LY2345, LY6701, Raji B-lymphoma B cell lymphoma, NHL (DLBCL, ABC/GCB), T-cell Lymphoma Lymphoma Immuno-Oncology , Oncology CDX, HuGEMM, MiXeno, PDX, Sygeneic
Assessing therapy response in patient-derived xenografts. 2021 J Janosch Ortmann et. al. NA NA NA NA NA
DNA-Damage-Induced Alternative Splicing of p53 2021 J Jing Chen et. al. AD0484 NA - Adrenal gland Cancer, T - Acute Lymphoblastic Leukemia NA NA NA
SynAI: An AI-driven Cancer Drugs Synergism Prediction Platform 2021 Kuan Yan et. al. NA NA NA Oncology Cell lines
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer 2019 LA Louise A Koopman et. al. LU0858, LU1868 NSCLC- Lung Cancer Lung Cancer Immuno-Oncology PDX
Resorbable and highly elastic block copolymers from 1,5-dioxepan-2-one and L-lactide with controlled tensile properties and hydrophilicity. 2002 M Maria Ryner et. al. AD0344 NA Acute Graft versus Host Disease NA CDX
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors 2016 M Mengmeng Yang et. al. LU0387, LU0858, LU1235, LU1868, LU3075 NSCLC- Lung Cancer Lung Cancer Oncology PDX
Robotic Radical Cystectomy Outcomes after Intervention for Prostate Cancer. 2021 NH Neel H Patel et. al. NA NA NA NA CDX, HuCell
Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population 2020 Q Qiang Zhao et. al. NA CCRCC - Kidney Cancer Kidney Cancer Immuno-Oncology , Oncology PDX
Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development. 2022 R Rajendra Kumari et. al. NA NA NA NA Organoids
Humanized Mouse Models for Immuno-oncology Drug Discovery 2023 Rajendra Kumari et. al. NA NA NA Immuno-Oncology NA
Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature 2016 S Sheng Guo et. al. CR0170, CR0193, CR0196, CR0231, CR0588, CR2110, CR2502, CR2520 NA Colorectal Cancer Oncology PDX
The design, analysis and application of mouse clinical trials in oncology drug development 2019 S Sheng Guo et. al. AD0484, AD10272, AL5511, BL3249 ADC - Bladder Cancer, Astrocytoma - Brain Cancer, SCC - Bladder Cancer, TCC - Bladder Cancer, Transition cell carcinoma - Bladder Cancer Bladder Cancer , Brain Cancer Immuno-Oncology , Inflammation CDX, HuGEMM, MiXeno
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification. 2022 T Ting Liu et. al. NA NA NA Oncology NA
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression 2017 TL Timothy L Lochmann et. al. LU5263 SCLC - Lung Cancer Lung Cancer Oncology PDX
The Immune Landscape of Cancer 2019 V Vésteinn Thorsson et. al. AD0484, AL5511, BL3249 NA - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder Cancer Bladder Cancer Oncology CDX, HuCell
EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab 2017 X Xiaohong Wang et. al. NA NA Gastric Cancer Oncology PDX
Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry 2018 X Xiaoyu An et. al. NA Ductal adenocarcinoma - Pancreatic Cancer Pancreatic Cancer Oncology MuPrime
Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice 2020 NA NA NA Gastric Cancer , Kidney Cancer , Liver Cancer , Lung Cancer , Melanoma , Ovarian Cancer Oncology PDX, Sygeneic
Tumor Purity in Preclinical Mouse Tumor Models 2022 NA NA NA NA Immuno-Oncology , Oncology PDX, Sygeneic
AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes 2016 NA AM7577 M5 - Acute Myeloid Leukemia Acute Myeloid Leukemia Oncology PDX
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations 2017 NA AM7577 NA Acute Myeloid Leukemia Oncology PDX
Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions 2018 NA LU0387 NSCLC- Lung Cancer Lung Cancer Oncology PDX
c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors 2017 NA NA NA Bladder Cancer , Gastric Cancer , Lung Cancer Immuno-Oncology , Oncology PDX
Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature 2016 NA CR0004, CR0010, CR0012, CR0024, CR0028, CR0029, CR0047, CR0133, CR11377 Mucinous adenocarcinoma - Gastric Cancer Colorectal Cancer Immuno-Oncology PDX
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer 2019 NA GA0060 NA Gastric Cancer Oncology PDX
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors 2017 NA CR2518, CR2545 NA Colorectal Cancer Oncology PDX
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells 2017 NA NA NA Pancreatic Cancer Oncology PDX
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models 2017 NA LU2503, LU5381 NSCLC- Lung Cancer Lung Cancer Immuno-Oncology , Inflammation PDX
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage 2021 NA NA NA NA Oncology PDX
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer 2018 NA LU0387 NA Lung Cancer Oncology PDX
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor 2019 NA NA NA Colorectal Cancer , Lung Cancer , Ovarian Cancer , Pancreatic Cancer Oncology PDX
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity 2018 NA GA0055 ADC - Gastric Cancer Gastric Cancer Immuno-Oncology , Oncology PDX
Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models 2023 NA NA NA NA Oncology PDX
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor 2017 NA CR3496, CR3547, CR3612, CR6227, MC3405 NA Colorectal Cancer Oncology PDX
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib 2018 NA CR1520, CR2502, CR2518, CR2520 NA Colorectal Cancer Oncology PDX
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies 2020 NA CR2518 ADC - Colorectal Cancer Colorectal Cancer Oncology PDX
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants 2019 NA NA NA GIST Oncology PDX
Selective RET kinase inhibition for patients with RET-altered cancers 2018 NA CR2518, CR2545 ADC - Colorectal Cancer, NSCLC- Lung Cancer Colorectal Cancer Oncology PDX
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT 2017 NA LY0257, LY2298 B cell lymphoma - Lymphoma, B cell lymphoma (ABC/GCB, MYD88 L265P) - Lymphoma, NHL - Lymphoma, NHL (DLBCL, ABC) - Lymphoma Lymphoma Oncology PDX
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function 2015 NA CR2506, CR3150 ADC, mucinous adenocarcinoma - Colorectal Cancer, Adenocarcinoma - Colorectal Cancer Colorectal Cancer Oncology PDX
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients 2019 NA LU1147, LU11693, LU2512, LU6405 NSCLC- Lung Cancer Lung Cancer Immuno-Oncology , Oncology PDX
A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology 2023 NA NA NA NA Oncology Organoids
New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids 2021 NA NA NA NA Oncology Organoids
Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells 2021 NA NA NA NA Immuno-Oncology , Inflammation NA
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases 2021 NA NA NA NA Immuno-Oncology , Inflammation NA
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment 2022 NA NA NA NA Immuno-Oncology , Inflammation NA
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models 2019 NA BL6078, SA9003, SK6005 NA Bladder Cancer , Sarcoma , Skin Cancer Oncology MuPrime
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties 2010 NA HCC827 NSCLC- Lung Cancer Lung Cancer Immuno-Oncology , Oncology HuGEMM, MiXeno
Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment 2001 NA NA NA NA Oncology HuGEMM, MiXeno
Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies 2022 NA NA NA Lymphoma Oncology Cell lines
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors 2016 NA HCC827, LU1235, LU1868 NSCLC- Lung Cancer Lung Cancer Oncology CDX, PDX
EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor 2015 NA HCC827, LU0387 NSCLC- Lung Cancer Lung Cancer Oncology CDX, PDX
Preclinical pharmacology modeling of chimeric antigen receptor T therapies 2021 NA NA NA NA Immuno-Oncology CDX, GEMM, HuCell, HuGEMM, Humanized models, MiXeno, MuPrime, Organoids, PDX, Sygeneic
Authentication, characterization and contamination detection of cell lines, xenografts and organoids by barcode deep NGS sequencing 2020 NA NA NA NA NA CDX, Cell lines, Organoids, PDX
Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib 2020 NA HCC827 NSCLC (EGFR hi) - Lung Cancer Lung Cancer Oncology CDX
A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease 2023 NA huPKD05 Kidney Disease ADPKD Genetic Disease 3D Cyst